JB Chemicals and Pharma Panoli facility concludes USFDA inspection no observations
Mumbai: JB Chemicals and Pharma has announced that the Company's API manufacturing facility- D9 located at Plot No. 5, GIDC, Panoli, Gujarat has concluded the U.S. Food and Drug Administration (USFDA) inspection with no observations.
The inspection was conducted from March 10, 2025 to March 13, 2025.
At the end of the inspection, the facility received “No Observations” and thus NO Form 483 was issued.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
"The Company remains committed to producing quality products, embedding a quality culture across the organization and continuously investing in systems, processes & training of its employees so that it can maintain the highest standards of quality and compliance for all its markets," JB Chemicals stated in a BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.